Director Cheryl Pegus purchases initial 1,770 shares of BSX at $56.49 for $99,987.30
Director Cheryl Pegus acquired her first position in Boston Scientific, purchasing 1,770 shares at $56.49 on 2026-05-20 for a total value of $99,987.30. The purchase occurs near the lower end of the 52-week range ($52.52–$109.50), with the stock currently down 47.8% from its 52-week high and down 4.0% over 30 days and 23.4% over 90 days. Boston Scientific reported strong fundamentals with $5.2B quarterly revenue, $1.3B net income, and 19.9% annual revenue growth, though the stock trades at a P/E of 23.91. This initiation of a director position during a period of weakness merits monitoring to determine whether subsequent transactions establish a pattern of accumulation or represent a one-time addition to holdings.